<DOC>
	<DOCNO>NCT00044512</DOCNO>
	<brief_summary>Evaluate anti-cancer activity ( e.g . proportion patient confirm complete response partial response ) patient advance , inoperable biopsy-proven hepatocellular carcinoma .</brief_summary>
	<brief_title>A Study Estimate Safety Efficacy Sorafenib ( BAY43-9006 ) Treatment Hepatocellular Carcinoma</brief_title>
	<detailed_description>In addition key secondary outcome parameter follow exploratory parameter evaluate subpopulation : - Pharmacokinetics ( PK ) profile Sorafenib - Plasma tissue tumor biomarkers</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytologically confirm primary hepatocellular carcinoma ( HCC ) Inoperable disease ( T2T4 , N , M0 M1 ) refuse surgery Measurable disease At least 1 bidimensionally measurable lesion least 2 cm compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) Presence least 1 follow : Alphafetoprotein great upper limit normal ( ULN ) Hepatitis C antibody positive Hepatitis B surface antigen positive Child 's Pugh class A B Candidate systemic therapy Fibrolamellar disease mixed histology Metastatic brain meningeal tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Liver Cancer</keyword>
	<keyword>Hepatocellular carcinoma ( HCC )</keyword>
</DOC>